{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/experience-matters-successful-impairment-studies#webpage",
"url": "https://www.fortrea.com/insights/experience-matters-successful-impairment-studies",
"name": "Experience That Matters in Successful Impairment Studies",
"description": "This Fortrea article explores the critical role of impairment studies in modern drug development and explains how hepatic and renal impairment assessments support clinical pharmacology strategies, drug metabolism evaluation, and regulatory labeling requirements. As regulatory agencies increasingly require sponsors to understand how medicines are processed in patients with varying levels of organ function, impairment studies provide essential information on pharmacokinetics, metabolism, safety considerations, and dosing recommendations. The article discusses the importance of designing the right impairment strategy based on a drug's metabolic profile, regulatory expectations, and development objectives, while highlighting approaches such as full, reduced, and hybrid study designs. It also examines how impairment studies can be integrated with broader clinical pharmacology programs, including human absorption, metabolism and excretion (hAME), drug metabolism and pharmacokinetics (DMPK), food effect, drug-drug interaction, QTc, and bioequivalence studies to support labeling packages, marketing authorization applications, and informed decision-making throughout the drug development pathway."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Experience That Matters in Successful Impairment Studies",
"item": "https://www.fortrea.com/insights/experience-matters-successful-impairment-studies"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/experience-matters-successful-impairment-studies#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/experience-matters-successful-impairment-studies#webpage"
},
"headline": "Impairment Studies in Drug Development: Supporting Clinical Pharmacology, Drug Metabolism and Regulatory Labeling Requirements | Fortrea Article",
"description": "This Fortrea article explores the critical role of impairment studies in modern drug development and explains how hepatic and renal impairment assessments support clinical pharmacology strategies, drug metabolism evaluation, and regulatory labeling requirements. As regulatory agencies increasingly require sponsors to understand how medicines are processed in patients with varying levels of organ function, impairment studies provide essential information on pharmacokinetics, metabolism, safety considerations, and dosing recommendations. The article discusses the importance of designing the right impairment strategy based on a drug's metabolic profile, regulatory expectations, and development objectives, while highlighting approaches such as full, reduced, and hybrid study designs. It also examines how impairment studies can be integrated with broader clinical pharmacology programs, including human absorption, metabolism and excretion (hAME), drug metabolism and pharmacokinetics (DMPK), food effect, drug-drug interaction, QTc, and bioequivalence studies to support labeling packages, marketing authorization applications, and informed decision-making throughout the drug development pathway.",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-04-14",
"dateModified": "2026-04-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-05/successful-impairment-studies-05-05.pdf",
"encodingFormat": "application/pdf"
}
}
]
}